Compare BZ & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZ | RDY |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | China | India |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 11.6B |
| IPO Year | 2021 | N/A |
| Metric | BZ | RDY |
|---|---|---|
| Price | $18.60 | $13.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $26.00 | $16.90 |
| AVG Volume (30 Days) | ★ 3.7M | 1.7M |
| Earning Date | 03-10-2026 | 01-20-2026 |
| Dividend Yield | ★ 0.91% | 0.53% |
| EPS Growth | ★ 69.83 | 5.58 |
| EPS | ★ 0.77 | 0.76 |
| Revenue | $1,125,491,208.00 | ★ $3,848,694,754.00 |
| Revenue This Year | $15.60 | $6.12 |
| Revenue Next Year | $13.18 | $2.58 |
| P/E Ratio | $24.11 | ★ $17.54 |
| Revenue Growth | ★ 12.66 | 11.09 |
| 52 Week Low | $13.28 | $12.26 |
| 52 Week High | $25.26 | $16.17 |
| Indicator | BZ | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 44.44 |
| Support Level | $18.95 | $13.13 |
| Resistance Level | $19.55 | $13.85 |
| Average True Range (ATR) | 0.53 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 8.39 | 48.46 |
Kanzhun's Boss Zhipin job platform connects job seekers and employers. Boss Zhipin is China's largest online recruitment platform based on monthly active users, or MAU, and was established in 2014. Kanzhun earns revenue by providing services to enterprise customers primarily through its mobile app, which promotes engagement between recruiters and workers and operates on a recommendation basis powered by artificial intelligence. The platform specializes in transportation, logistics, construction, and service-based industries. About 85% of the companies looking to hire are small and medium-size enterprises. Its main competitors are 58.com, 51job, and Zhilian Zhaopin. Tencent has a 9.2% stake in Kanzhun.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.